Abcellera Biologics Stock Price Prediction
| ABCL Stock | USD 4.99 0.07 1.42% |
Momentum 73
Buy Stretched
Oversold | Overbought |
Quarterly Earnings Growth 0.459 | EPS Estimate Next Quarter (0.14) | EPS Estimate Current Year (0.65) | EPS Estimate Next Year (0.63) | Wall Street Target Price 8.4286 |
Using Abcellera Biologics hype-based prediction, you can estimate the value of Abcellera Biologics from the perspective of Abcellera Biologics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Abcellera Biologics using Abcellera Biologics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Abcellera using crowd psychology based on the activity and movement of Abcellera Biologics' stock price.
Abcellera Biologics Short Interest
An investor who is long Abcellera Biologics may also wish to track short interest. As short interest increases, investors should be becoming more worried about Abcellera Biologics and may potentially protect profits, hedge Abcellera Biologics with its derivative instruments, or be ready for some potential downside.
200 Day MA 2.821 | Short Percent 0.1323 | Short Ratio 4.07 | Shares Short Prior Month 26.5 M | 50 Day MA 3.0822 |
Abcellera Biologics Hype to Price Pattern
Investor biases related to Abcellera Biologics' public news can be used to forecast risks associated with an investment in Abcellera. The trend in average sentiment can be used to explain how an investor holding Abcellera can time the market purely based on public headlines and social activities around Abcellera Biologics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Abcellera Biologics' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Abcellera Biologics.
Abcellera Biologics Implied Volatility | 1.41 |
Abcellera Biologics' implied volatility exposes the market's sentiment of Abcellera Biologics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Abcellera Biologics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Abcellera Biologics stock will not fluctuate a lot when Abcellera Biologics' options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Abcellera Biologics to buy its stock at a price that has no basis in reality. In that case, they are not buying Abcellera because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Abcellera Biologics after-hype prediction price | USD 4.94 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Prediction based on Rule 16 of the current Abcellera contract
Based on the Rule 16, the options market is currently suggesting that Abcellera Biologics will have an average daily up or down price movement of about 0.0881% per day over the life of the 2025-10-17 option contract. With Abcellera Biologics trading at USD 4.99, that is roughly USD 0.004397 . If you think that the market is fully incorporating Abcellera Biologics' daily price movement you should consider acquiring Abcellera Biologics options at the current volatility level of 1.41%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Abcellera | Build AI portfolio with Abcellera Stock |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Abcellera Biologics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Abcellera Biologics After-Hype Price Prediction Density Analysis
As far as predicting the price of Abcellera Biologics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Abcellera Biologics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Abcellera Biologics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Abcellera Biologics Estimiated After-Hype Price Volatility
In the context of predicting Abcellera Biologics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Abcellera Biologics' historical news coverage. Abcellera Biologics' after-hype downside and upside margins for the prediction period are 0.25 and 10.49, respectively. We have considered Abcellera Biologics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Abcellera Biologics is relatively risky at this time. Analysis and calculation of next after-hype price of Abcellera Biologics is based on 3 months time horizon.
Abcellera Biologics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Abcellera Biologics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Abcellera Biologics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Abcellera Biologics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
1.20 | 5.55 | 0.02 | 0.81 | 9 Events / Month | 6 Events / Month | In about 9 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
4.99 | 4.94 | 0.41 |
|
Abcellera Biologics Hype Timeline
Abcellera Biologics is presently traded for 4.99. The entity has historical hype elasticity of 0.02, and average elasticity to hype of competition of 0.81. Abcellera is forecasted to increase in value after the next headline, with the price projected to jump to 4.94 or above. The average volatility of media hype impact on the company the price is over 100%. The price upswing on the next news is projected to be 0.41%, whereas the daily expected return is presently at 1.2%. The volatility of related hype on Abcellera Biologics is about 824.26%, with the expected price after the next announcement by competition of 5.80. The company reported the previous year's revenue of 28.83 M. Net Loss for the year was (162.86 M) with loss before overhead, payroll, taxes, and interest of (147.35 M). Given the investment horizon of 90 days the next forecasted press release will be in about 9 days. Check out Abcellera Biologics Basic Forecasting Models to cross-verify your projections.Abcellera Biologics Related Hype Analysis
Having access to credible news sources related to Abcellera Biologics' direct competition is more important than ever and may enhance your ability to predict Abcellera Biologics' future price movements. Getting to know how Abcellera Biologics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Abcellera Biologics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| DNA | Ginkgo Bioworks Holdings | (0.88) | 11 per month | 4.29 | 0.12 | 14.73 | (7.43) | 29.69 | |
| CVAC | CureVac NV | 0.24 | 8 per month | 2.34 | 0.13 | 7.43 | (4.69) | 39.05 | |
| IOVA | Iovance Biotherapeutics | 0.05 | 7 per month | 9.37 | 0.03 | 12.43 | (7.25) | 50.12 | |
| KRYS | Krystal Biotech | 3.49 | 10 per month | 0.00 | (0.09) | 4.17 | (3.64) | 18.32 | |
| CERT | Certara | (0.16) | 11 per month | 0.00 | (0.17) | 4.30 | (4.45) | 15.62 | |
| BEAM | Beam Therapeutics | 2.22 | 9 per month | 4.24 | 0.07 | 6.28 | (4.15) | 26.62 | |
| NTLA | Intellia Therapeutics | (0.14) | 9 per month | 5.45 | 0.18 | 8.60 | (5.29) | 36.46 | |
| PACB | Pacific Biosciences of | (0.06) | 11 per month | 3.50 | 0.08 | 14.00 | (6.67) | 29.00 | |
| TWST | Twist Bioscience Corp | 1.30 | 11 per month | 0.00 | (0.05) | 6.04 | (7.89) | 15.74 |
Abcellera Biologics Additional Predictive Modules
Most predictive techniques to examine Abcellera price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Abcellera using various technical indicators. When you analyze Abcellera charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Abcellera Biologics Predictive Indicators
The successful prediction of Abcellera Biologics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Abcellera Biologics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Abcellera Biologics based on analysis of Abcellera Biologics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Abcellera Biologics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Abcellera Biologics's related companies. | 2022 | 2023 | 2024 | 2025 (projected) | Days Sales Outstanding | 29.02 | 618.0 | 1.2K | 1.2K | PTB Ratio | 2.34 | 1.43 | 0.82 | 0.78 |
Story Coverage note for Abcellera Biologics
The number of cover stories for Abcellera Biologics depends on current market conditions and Abcellera Biologics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Abcellera Biologics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Abcellera Biologics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Abcellera Biologics Short Properties
Abcellera Biologics' future price predictability will typically decrease when Abcellera Biologics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Abcellera Biologics often depends not only on the future outlook of the potential Abcellera Biologics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Abcellera Biologics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 294.3 M | |
| Cash And Short Term Investments | 625.6 M |
Check out Abcellera Biologics Basic Forecasting Models to cross-verify your projections. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.459 | Earnings Share (0.56) | Revenue Per Share | Quarterly Revenue Growth (0.57) | Return On Assets |
The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.